GLP-3 Research Guide
Research Overview
GLP-3 (LY3437943) is an investigational single-molecule peptide that acts as an agonist at three receptors: the glucose-dependent insulinotropic polypeptide receptor (GIPR), the glucagon-like peptide-1 receptor (GLP-1R), and the glucagon receptor (GCGR). It has been studied in preclinical and clinical metabolic research as a triple-hormone-receptor agonist. This is a research compound and is not intended for human consumption.
Structural & Class Overview
Investigational triple-agonist peptide acting across three class B G-protein-coupled receptors (GIPR, GLP-1R, GCGR). Combines incretin-receptor agonism with glucagon-receptor agonism in one molecule; part of the emerging multi-receptor incretin/glucagon peptide family.
General Research Interest
Research interest includes tri-agonist receptor pharmacology and signaling balance across three targets, energy-metabolism pathways in preclinical models, hepatic lipid content in laboratory steatosis models, and comparative study versus single- and dual-agonist incretin peptides.
Storage Considerations
Typically supplied as a lyophilized powder. General research handling keeps lyophilized material cold and protected from light and moisture; reconstituted solutions are generally refrigerated and used within a limited window. For laboratory research handling only.
Testing & Quality Considerations
Quality considerations include HPLC purity analysis, mass-spectrometry identity confirmation of the expected mass, and verification of each batch against its Certificate of Analysis (COA). Public research information on this compound is investigational and evolving; this page will be expanded as additional documentation is reviewed.
References
- Triple-Hormone-Receptor Agonist GLP-3 for Obesity — Phase 2 Trial (NEJM)
- A Study of GLP-3 (LY3437943) — ClinicalTrials.gov NCT05929066
- Triple hormone receptor agonist retatrutide for MASLD: phase 2a trial (Nature Medicine)
References are provided for scientific context. Linked sources are independent and not affiliated with iNGEN MD.
